BioAtla (NASDAQ:BCAB – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter.
BioAtla (NASDAQ:BCAB – Get Free Report) last released its quarterly earnings data on Tuesday, March 26th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.12. On average, analysts expect BioAtla to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
BioAtla Stock Performance
BCAB stock traded down $0.01 during trading on Wednesday, hitting $3.08. 29,710 shares of the company’s stock traded hands, compared to its average volume of 550,998. The business has a fifty day simple moving average of $2.86 and a 200 day simple moving average of $2.31. BioAtla has a 52 week low of $1.24 and a 52 week high of $4.07. The stock has a market capitalization of $148.15 million, a price-to-earnings ratio of -1.19 and a beta of 1.23.
Analyst Ratings Changes
Check Out Our Latest Research Report on BioAtla
About BioAtla
BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
Recommended Stories
- Five stocks we like better than BioAtla
- How is Compound Interest Calculated?
- How to Read an Earnings Report | Step by Step Guide with Tips
- Investing in large cap stocks: Diving into big caps
- Datadog: In the Doghouse or Pullback to the Buyzone?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Celsius Stock’s Post-Earnings Morning Dip, Better than Coffee
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.